FDA: Embryo Toxic effects of topiramate
The Food and Drug Administration (FDA) indicates an increased risk of cleft lip and palate while taking topiramate during pregnancy.
Topiramate is used to treat epilepsy and for migraine prophylaxis. An increased risk of cleft lip and cleft palate in newborns is especially when taken in the first trimester of pregnancy. The prevalence is 1.4% according to FDA topiramate - compared to 0.38 to 0.55% for the use of other antiepileptic drugs and 0.07% in women not taking such drugs.
leaflet and SPC will be complemented with appropriate instructions.
Source:
Safety Information the FDA of 4 March 2011
Monday, March 7, 2011
Sunday, March 6, 2011
Sympathy Saying For Dogs
Homeopathic first consultation - the anamnesis
A homeopathic treatment under the rules of classical homeopathy is different from a conventional treatment, primarily by their approach. In contrast to traditional medicine, in which "the skin, eczema treatment, something prescribed for the inflammation and the fever is lowered, you look in homeopathy (as in many other alternative therapies) to people as a whole. It is believed that the organism is basically in a position to heal itself. Sometimes it is necessary to initiate this process of self-healing. And that's what means do homeopaths do homeopathic remedies!
existence of diseases or symptoms already longer, a so-called Konstituionsbehandlung makes sense. In this case - drawn up a comprehensive picture of the sick people - according to a holistic view. For this first consultation takes a homeopath * much time.
A first consultation for treatment under the rules of classical homeopathy has about three hours. Two hours are required for recording the case history / investigation. Subsequently, the recorded symptoms evaluated (Repertory) and selected a homeopathic single remedy.
Some patients appear so long a conversation as a hurdle: "I have a headache What. I talk for two hours? "It has to do not worry, as time goes by generally very quick!
Here is a summary of how a first consultation in my Natural Healing for Children and Women expires in about.
possible after receiving the personal information and clarification in advance of existing questions to homeopathy, first discussed the main complaint. Which appeal was to begin crucial a homeopathic treatment? This should preferably be described in detail by the patient.
is significant homöopathishe for a history that The patient in this part of the conversation does not interrupted. All she spontaneously expresses is of great importance. Even little things can be very important.
set out the main complaint is exhaustive, further complaints be obtained without direct the conversation in a certain direction. It will be made aware of neutral questions such as: "What else is there?", "What they also depressed?" Thus, important aspects of the current health of the patient are recorded.
If I get a more accurate description of a complaint, z: B: headache need, I will ask more questions here: "Tell me more about your headache."
It is initially somewhat unusual for Patients who had been to do nothing with homeopathy to answer such vague questions, but you get used to it pretty quickly. I've never seen that one patient out of ideas to do so. The advantage of these open questions is that the patients are intuitive to the point and bring the homeopath for us essential information.
covered all physical complaints, discussed the emotional and mental condition. Thus, the so-called spontaneous reporting is complete. Now completed, the symptoms (especially the main complaint / chief complaints) by specific questions and an investigation. The image
for example, is complemented by general questions. to sleep, appetite / digestion, menstruation, sensitivity to cold or heat, power and general ability to work
etc. The conclusion of the history of the own pre-existing conditions if they have not already taken, and their treatment. Even made by childhood diseases are of interest here, especially if there was a complicated course.
The diseases in the family finally shed light on how the treatment is expected to run and how profound the impact has to be chosen homeopathic remedies.
goes after the anamnesis, the patient first Non-medicated home, for now a detailed analysis of the recorded information is from the first consultation, in which the patient no longer needs to be here. How quickly a good and long term acting agent can be found depends on many factors, which I at this point but can not go into detail.
I prescribe homeopathic single remedy in small doses as a globules (beads) or drops, I just declare their income. If necessary, they are supplemented by Schuessler salts, Bach flower remedies and herbal products. Depending on the nature of the complaints directed to the observation period up to the next event in my practice. In general, these are chronic diseases 4 to 6 weeks, but also closely monitored (eg in atopic dermatitis) may be advised.
It is clear that in this article is not possible to discuss every detail of the first history in great detail while staying within a manageable framework. All of the outstanding questions I will answer you personally:
telephone: 0179 9084948 or 030 42019670,
writing about the contact form or
in my practice
* The notation in female form includes the male and vice-versa.
A homeopathic treatment under the rules of classical homeopathy is different from a conventional treatment, primarily by their approach. In contrast to traditional medicine, in which "the skin, eczema treatment, something prescribed for the inflammation and the fever is lowered, you look in homeopathy (as in many other alternative therapies) to people as a whole. It is believed that the organism is basically in a position to heal itself. Sometimes it is necessary to initiate this process of self-healing. And that's what means do homeopaths do homeopathic remedies!
existence of diseases or symptoms already longer, a so-called Konstituionsbehandlung makes sense. In this case - drawn up a comprehensive picture of the sick people - according to a holistic view. For this first consultation takes a homeopath * much time.
A first consultation for treatment under the rules of classical homeopathy has about three hours. Two hours are required for recording the case history / investigation. Subsequently, the recorded symptoms evaluated (Repertory) and selected a homeopathic single remedy.
Some patients appear so long a conversation as a hurdle: "I have a headache What. I talk for two hours? "It has to do not worry, as time goes by generally very quick!
Here is a summary of how a first consultation in my Natural Healing for Children and Women expires in about.
possible after receiving the personal information and clarification in advance of existing questions to homeopathy, first discussed the main complaint. Which appeal was to begin crucial a homeopathic treatment? This should preferably be described in detail by the patient.
is significant homöopathishe for a history that The patient in this part of the conversation does not interrupted. All she spontaneously expresses is of great importance. Even little things can be very important.
set out the main complaint is exhaustive, further complaints be obtained without direct the conversation in a certain direction. It will be made aware of neutral questions such as: "What else is there?", "What they also depressed?" Thus, important aspects of the current health of the patient are recorded.
If I get a more accurate description of a complaint, z: B: headache need, I will ask more questions here: "Tell me more about your headache."
It is initially somewhat unusual for Patients who had been to do nothing with homeopathy to answer such vague questions, but you get used to it pretty quickly. I've never seen that one patient out of ideas to do so. The advantage of these open questions is that the patients are intuitive to the point and bring the homeopath for us essential information.
covered all physical complaints, discussed the emotional and mental condition. Thus, the so-called spontaneous reporting is complete. Now completed, the symptoms (especially the main complaint / chief complaints) by specific questions and an investigation. The image
for example, is complemented by general questions. to sleep, appetite / digestion, menstruation, sensitivity to cold or heat, power and general ability to work
etc. The conclusion of the history of the own pre-existing conditions if they have not already taken, and their treatment. Even made by childhood diseases are of interest here, especially if there was a complicated course.
The diseases in the family finally shed light on how the treatment is expected to run and how profound the impact has to be chosen homeopathic remedies.
goes after the anamnesis, the patient first Non-medicated home, for now a detailed analysis of the recorded information is from the first consultation, in which the patient no longer needs to be here. How quickly a good and long term acting agent can be found depends on many factors, which I at this point but can not go into detail.
I prescribe homeopathic single remedy in small doses as a globules (beads) or drops, I just declare their income. If necessary, they are supplemented by Schuessler salts, Bach flower remedies and herbal products. Depending on the nature of the complaints directed to the observation period up to the next event in my practice. In general, these are chronic diseases 4 to 6 weeks, but also closely monitored (eg in atopic dermatitis) may be advised.
It is clear that in this article is not possible to discuss every detail of the first history in great detail while staying within a manageable framework. All of the outstanding questions I will answer you personally:
telephone: 0179 9084948 or 030 42019670,
writing about the contact form or
in my practice
* The notation in female form includes the male and vice-versa.
Friday, March 4, 2011
Milena Velba As A Nurse
hours Saturday in March
Also in March, I would have opened on a Saturday my naturopathic practice in homeopathy for children and women in Berlin Friedrichshain.
Are there problems during the week to find an appointment for an initial medical history, offers Saturday hours are a good alternative to late night appointments on
Also in March, I would have opened on a Saturday my naturopathic practice in homeopathy for children and women in Berlin Friedrichshain.
Are there problems during the week to find an appointment for an initial medical history, offers Saturday hours are a good alternative to late night appointments on
26th March 2011
Schedules Free your phone in time
01,799,084,948 or 030-42019670
Redline Movie Upskirt
EU: pirfenidone for the treatment of idiopathic pulmonary fibrosis admitted
The EU Commission has pirfenidone (Esbriet, InterMune Europe Ltd) approved orphan drug for the treatment of idiopathic pulmonary fibrosis.
The TGF-beta inhibitor is pirfenidone for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis, IPF), indicated for the previously approved drug therapy was not available. As it is granted an orphan drug extended patent protection, ensuring a 10-year exclusive marketing rights until 2021. In Germany, according to InterMune with a launch expected in September 2011.
administered orally pirfenidone inhibits the synthesis of TGF-beta. TGF-beta controls many cellular functions and plays in the development of fibrosis, a key role. In addition, pirfenidone inhibits the synthesis of TNF-alpha, which is actively involved in inflammatory processes.
Source:
ABDA database of 4 March 2011
The EU Commission has pirfenidone (Esbriet, InterMune Europe Ltd) approved orphan drug for the treatment of idiopathic pulmonary fibrosis.
The TGF-beta inhibitor is pirfenidone for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis, IPF), indicated for the previously approved drug therapy was not available. As it is granted an orphan drug extended patent protection, ensuring a 10-year exclusive marketing rights until 2021. In Germany, according to InterMune with a launch expected in September 2011.
administered orally pirfenidone inhibits the synthesis of TGF-beta. TGF-beta controls many cellular functions and plays in the development of fibrosis, a key role. In addition, pirfenidone inhibits the synthesis of TNF-alpha, which is actively involved in inflammatory processes.
Source:
ABDA database of 4 March 2011
Beste Look Alike Uggs
EMA: bevacizumab in breast cancer only in combination with paclitaxel
bevacizumab (Avastin) for the treatment of breast cancer in the future may only be used in combination with paclitaxel.
bevacizumab (Avastin), which was approved in the EU so far include the first-line treatment of metastatic breast cancer in combination with paclitaxel or docetaxel, may in future only with paclitaxel be used. The decision by the European Commission is based on a recommendation of the Committee for Human Medicinal Products of the EMEA (CHMP), who had performed in 2010 to reassess the risk-benefit ratio for this combination therapy. Here, the risk-benefit ratio for the combination of bevacizumab plus paclitaxel was still positive, the combination of bevacizumab plus docetaxel, however, been rated negatively.
In the United States intends to bevacizumab FDA approval for breast cancer, where bevacizumab is used in combination with paclitaxel escape, complete.
The Drug Commission of the German Medical Association - had already in 2008, press releases critical of the approval for bevacizumab expressed in combination with paclitaxel in metastatic breast cancer and shares the concerns of the FDA. From the perspective of AkdÄ should be approved in Europe continues to be used combination with paclitaxel in breast cancer, therefore, extremely cautious. The affected patients should be advised of the expected marginal benefit and the rare but serious side effects before an individual decision is made for this treatment option.
Source:
ABDA databases: report of 3 March 2011
bevacizumab (Avastin) for the treatment of breast cancer in the future may only be used in combination with paclitaxel.
bevacizumab (Avastin), which was approved in the EU so far include the first-line treatment of metastatic breast cancer in combination with paclitaxel or docetaxel, may in future only with paclitaxel be used. The decision by the European Commission is based on a recommendation of the Committee for Human Medicinal Products of the EMEA (CHMP), who had performed in 2010 to reassess the risk-benefit ratio for this combination therapy. Here, the risk-benefit ratio for the combination of bevacizumab plus paclitaxel was still positive, the combination of bevacizumab plus docetaxel, however, been rated negatively.
In the United States intends to bevacizumab FDA approval for breast cancer, where bevacizumab is used in combination with paclitaxel escape, complete.
The Drug Commission of the German Medical Association - had already in 2008, press releases critical of the approval for bevacizumab expressed in combination with paclitaxel in metastatic breast cancer and shares the concerns of the FDA. From the perspective of AkdÄ should be approved in Europe continues to be used combination with paclitaxel in breast cancer, therefore, extremely cautious. The affected patients should be advised of the expected marginal benefit and the rare but serious side effects before an individual decision is made for this treatment option.
Source:
ABDA databases: report of 3 March 2011
Thursday, March 3, 2011
Paramedic Program Accelerated In Ny
FDA reviewed risk for heart attacks in abacavir-taking
The Food and Drug Administration (FDA) is examining whether there is a connection between the use of abacavir and Herzinfarken.
The treatment of HIV-infected individuals with antiviral abacavir went on observational studies and a randomized controlled trial, associated with an increased risk of heart attack. In other studies, these findings could not be confirmed. A meta-analysis of 26 studies led the FDA also no increased risk of heart attack while taking abacavir.
Source:
FDA safety information from 1 March 2011
The Food and Drug Administration (FDA) is examining whether there is a connection between the use of abacavir and Herzinfarken.
The treatment of HIV-infected individuals with antiviral abacavir went on observational studies and a randomized controlled trial, associated with an increased risk of heart attack. In other studies, these findings could not be confirmed. A meta-analysis of 26 studies led the FDA also no increased risk of heart attack while taking abacavir.
Source:
FDA safety information from 1 March 2011
Wedding Card Messages For Fiance
FDA: Low magnesium levels by long-term use of PPI
The Food and Drug Administration (FDA) indicates that there may be in long-term use of proton pump inhibitors (PPIs) in hypomagnesaemia.
The prescription high-dose PPI as esomeprazole, Dexlansoprazol, Lansoprazole, omeprazole, pantoprazole and rabeprazole include in long-term use (usually one year) are at increased risk of hypomagnesemia. In about a quarter of the cases of magnesium deficiency is not compensated by magnesium substitution, this had to be sold PPI. In the Summary of PPIs an appropriate warning is received.
case of OTC PPIs, which are lower dose and only for a two-week treatment up to three times provided in states the FDA on the risk of hypomagnesemia as very low.
Source:
safety information to the FDA of 2 March 2011
The Food and Drug Administration (FDA) indicates that there may be in long-term use of proton pump inhibitors (PPIs) in hypomagnesaemia.
The prescription high-dose PPI as esomeprazole, Dexlansoprazol, Lansoprazole, omeprazole, pantoprazole and rabeprazole include in long-term use (usually one year) are at increased risk of hypomagnesemia. In about a quarter of the cases of magnesium deficiency is not compensated by magnesium substitution, this had to be sold PPI. In the Summary of PPIs an appropriate warning is received.
case of OTC PPIs, which are lower dose and only for a two-week treatment up to three times provided in states the FDA on the risk of hypomagnesemia as very low.
Source:
safety information to the FDA of 2 March 2011
Tuesday, March 1, 2011
Free Severe Caning Films
FDA: roflumilast for the treatment of chronic obstructive pulmonary disease admitted
The Food and Drug Administration (FDA) has roflumilast (DalirespTM, Forest) approved for the treatment of patients with severe chronic obstructive pulmonary disease (COPD).
The phosphodiesterase4 inhibitors (PDE-4) inhibitor roflumilast is indicated for the reduction in the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and exacerbations of VTE. Roflumilast is not a bronchodilator and is not suitable for the treatment of acute bronchospasm.
by the European Commission roflumilast (Daxas) already admitted in June 2010.
Source:
press release the FDA from 1 March 2011
The Food and Drug Administration (FDA) has roflumilast (DalirespTM, Forest) approved for the treatment of patients with severe chronic obstructive pulmonary disease (COPD).
The phosphodiesterase4 inhibitors (PDE-4) inhibitor roflumilast is indicated for the reduction in the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and exacerbations of VTE. Roflumilast is not a bronchodilator and is not suitable for the treatment of acute bronchospasm.
by the European Commission roflumilast (Daxas) already admitted in June 2010.
Source:
press release the FDA from 1 March 2011
Denisemilani.com Issues
BfArM: ketoprofen-containing topical drugs - Change Product
BfArM The associated into force in stages (stage II) 1 April 2011, the product information from ketoprofen-containing medicines for topical application to change.
to continue the product documentation photosensitivity and hypersensitivity reactions are given to non-steroidal anti-inflammatory and skin allergies to ketoprofen, tiaprofenic acid, fenofibrate, UV blockers or perfumes in history as contraindications. In addition, it should be noted that the hands should be washed thoroughly after application of ketoprofen-containing medicines. Treatment should be stopped immediately if a skin reaction by the drug or by a product with UV-blocker octocrylene (Co-Sensibilisierung!) shows. The treated areas should be protected by wearing clothing from sunlight during and until two weeks after the treatment - even if it is cloudy. Side effects in addition to local skin reactions such as erythema, pruritus or burning sensation and hypersensitivity reactions and photosensitization are given. As a rare, severe reaction to be called bullous or "phlyctenular" (by vesicles or pustules characterized) eczema.
to a later date yet to be created warn a pictogram on the carton before photosensitization. It is also planned, ketoprofen-containing drugs for cutaneous application again prescription to imply.
should also develop the manufacturers a so-called education program that includes the following:
Source:
BfArM: News and updates in the field of pharmacovigilance
BfArM The associated into force in stages (stage II) 1 April 2011, the product information from ketoprofen-containing medicines for topical application to change.
to continue the product documentation photosensitivity and hypersensitivity reactions are given to non-steroidal anti-inflammatory and skin allergies to ketoprofen, tiaprofenic acid, fenofibrate, UV blockers or perfumes in history as contraindications. In addition, it should be noted that the hands should be washed thoroughly after application of ketoprofen-containing medicines. Treatment should be stopped immediately if a skin reaction by the drug or by a product with UV-blocker octocrylene (Co-Sensibilisierung!) shows. The treated areas should be protected by wearing clothing from sunlight during and until two weeks after the treatment - even if it is cloudy. Side effects in addition to local skin reactions such as erythema, pruritus or burning sensation and hypersensitivity reactions and photosensitization are given. As a rare, severe reaction to be called bullous or "phlyctenular" (by vesicles or pustules characterized) eczema.
to a later date yet to be created warn a pictogram on the carton before photosensitization. It is also planned, ketoprofen-containing drugs for cutaneous application again prescription to imply.
should also develop the manufacturers a so-called education program that includes the following:
- twice annually releases about the risk of photosensitization to doctors and health professionals
- involvement of pharmacists (educational material for patients to be discharged to the topical ketoprofen-containing drugs )
- targeted messages about the dangers of photosensitivity reactions, for example, on websites of scientific societies and medical journals
- checklist for prescribers to ensure safe practice in relation to the risks (Eg, sunscreen, hand washing)
- to patient-related information (regular press releases on the websites of national drug regulatory authorities).
Source:
BfArM: News and updates in the field of pharmacovigilance
Subscribe to:
Posts (Atom)